title: Current status and future perspectives for yttrium-90 ((90)Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma.
abstract: Haematopoietic SCT is currently considered a therapeutic option mainly in relapsed or refractory non-Hodgkin's lymphoma (NHL) owing to high post-transplantation relapse rates and significant toxicity of conventional myeloablative conditioning for allogeneic SCT. Radiolabelled immunotherapy combines the benefits of monoclonal antibody targeting with therapeutic doses of radiation, and is a promising advance in the treatment of malignant lymphomas. It is now under investigation as a component of conditioning prior to SCT, with the aim of improving outcomes following SCT without increasing the toxicity of high-dose chemotherapy pre-transplant conditioning. An expert panel met at a European workshop in November 2006 to review the latest data on radiolabelled immunotherapy in the transplant setting, and its potential future directions, with a focus on (90)Y-ibritumomab tiuxetan. They reviewed data on the combination of standard/high/escalating dose (90)Y-ibritumomab tiuxetan with high-dose chemotherapy, and high/escalating dose (90)Y-ibritumomab tiuxetan as the sole myeloablative agent, prior to autologous SCT, and also (90)Y-ibritumomab tiuxetan as a component of reduced intensity conditioning prior to allogeneic SCT. The preliminary data are highly promising in terms of conditioning tolerability and patient outcomes following transplant; further phase II studies are now needed to consolidate these data and to investigate specific patient populations and NHL subtypes.
authors.affiliation: Institut d'Hématologie, Hôpital Saint-Louis, Paris, France. christian.gisselbrecht@sls.ap-hop-paris.fr
authors.forename: C
authors.initials: C
authors.lastname: Gisselbrecht
authors.forename: W
authors.initials: W
authors.lastname: Bethge
authors.forename: R F
authors.initials: RF
authors.lastname: Duarte
authors.forename: A M
authors.initials: AM
authors.lastname: Gianni
authors.forename: B
authors.initials: B
authors.lastname: Glass
authors.forename: C
authors.initials: C
authors.lastname: Haioun
authors.forename: G
authors.initials: G
authors.lastname: Martinelli
authors.forename: A
authors.initials: A
authors.lastname: Nagler
authors.forename: R
authors.initials: R
authors.lastname: Pettengell
authors.forename: A
authors.initials: A
authors.lastname: Sureda
authors.forename: H
authors.initials: H
authors.lastname: Tilly
authors.forename: K
authors.initials: K
authors.lastname: Wilson
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D019653:Myeloablative Agonists / Q000627:therapeutic use*; D019172:Transplantation Conditioning / Q000379:methods; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
chemical_list: D000911:Antibodies, Monoclonal; D019653:Myeloablative Agonists; C422802:ibritumomab tiuxetan